These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33414441)

  • 21. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.
    Li W; Zheng D; Zhang Y; Yang S; Su N; Bakhoum M; Zhang G; Naderinezhad S; Mao Z; Wang Z; Zhou T
    Res Sq; 2023 Oct; ():. PubMed ID: 37886478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
    Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
    [No Abstract]   [Full Text] [Related]  

  • 23. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
    Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
    Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
    Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
    Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
    Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
    Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
    Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
    J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
    Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
    Shafran JS; Andrieu GP; Györffy B; Denis GV
    Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
    J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency.
    Wen YC; Chen WY; Tram VTN; Yeh HL; Chen WH; Jiang KC; Abou-Kheir W; Huang J; Hsiao M; Liu YN
    Cell Death Dis; 2022 Mar; 13(3):252. PubMed ID: 35306527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
    Lin LC; Gao AC; Lai CH; Hsieh JT; Lin H
    Cancer Lett; 2017 Apr; 391():74-82. PubMed ID: 28109910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.
    Shankar E; Franco D; Iqbal O; Moreton S; Kanwal R; Gupta S
    Toxicol Appl Pharmacol; 2020 Oct; 404():115200. PubMed ID: 32805266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
    Bae SY; Bergom HE; Day A; Greene JT; Sychev ZE; Larson G; Corey E; Plymate SR; Freedman TS; Hwang JH; Drake JM
    Front Endocrinol (Lausanne); 2023; 14():1093332. PubMed ID: 37065756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.
    Patel GK; Chugh N; Tripathi M
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31547070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
    Sreekumar A; Saini S
    Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.